Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on CVRx and keeping the price target at $11.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
William Plovanic has given his Buy rating due to a combination of factors tied to CVRx’s recent performance and outlook. He notes that the company’s preliminary fourth-quarter revenue exceeded both his estimates and market expectations, reflecting solid execution and deeper penetration in key accounts. Management’s 2026 revenue forecast, calling for double‑digit growth with strong gross margins, is broadly consistent with his model and signals a sustainable growth trajectory. He also highlights the company’s continued expansion of its sales force and expectations that these newer hires will become more productive, supporting a rebound in U.S. growth.
Plovanic further points to strategic initiatives that could materially increase the company’s market opportunity. The BENEFIT-HF trial, now cleared by the FDA and seeking CMS IDE Category B coverage, is designed to evaluate Barostim in a broader heart failure population and could potentially triple CVRx’s addressable market if successful. At the same time, the recently amended and upsized term loan facility provides additional capital with an extended interest‑only period, giving CVRx greater financial flexibility to fund growth and clinical programs. Taken together, these operational, clinical, and financial drivers underpin his positive view and support his Buy recommendation on the stock.
According to TipRanks, Plovanic is a 4-star analyst with an average return of 4.0% and a 46.69% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Insulet, and TransMedics Group.